Mirati Therapeutics, Inc. MRTX
We take great care to ensure that the data presented and summarized in this overview for Mirati Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MRTX
View all-
Sawtooth Solutions, LLC3.14MShares$05.07% of portfolio
-
International Biotechnology Trust PLC London, X0216KShares$03.19% of portfolio
-
Tekla Capital Management LLC65.5KShares$00.09% of portfolio
-
Kellner Capital, LLC New York, NY41.4KShares$04.38% of portfolio
-
Brinker Capital Investments, LLC22.7KShares$00.02% of portfolio
-
Agf Investments LLC Boston, MA22.1KShares$00.14% of portfolio
-
Virginia Retirement Systems Et Al Richmond, VA21.4KShares$00.01% of portfolio
-
Jefferies Group LLC New York, NY21KShares$00.01% of portfolio
-
Eaton Vance Management Boston, MA10KShares$00.0% of portfolio
-
Dowling & Yahnke LLC San Diego, CA7.9KShares$00.26% of portfolio
Latest Institutional Activity in MRTX
Top Purchases
Top Sells
About MRTX
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Insider Transactions at MRTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 23
2024
|
Boxer Capital, LLC |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,658,104
-100.0%
|
-
|
|
Jan 23
2024
|
Boxer Capital, LLC |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,201,440
-100.0%
|
-
|
|
Jan 23
2024
|
Carol Giltner Gallagher |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,363
-76.3%
|
-
|
|
Jan 23
2024
|
Charles M Baum Founder, President, and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
237,871
-78.01%
|
-
|
|
Jan 23
2024
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
154,996
-73.06%
|
-
|
|
Jan 23
2024
|
Alan B. Sandler Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
79,865
-62.88%
|
-
|
|
Jan 23
2024
|
Maria E Martinez |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,273
-58.12%
|
-
|
|
Jan 23
2024
|
Benjamin Hickey EVP, Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
117,028
-68.23%
|
-
|
|
Jan 23
2024
|
John B Moriarty Chief Legal Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
72,335
-50.47%
|
-
|
|
Jan 23
2024
|
Aaron Ondrey Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
39,461
-52.9%
|
-
|
|
Jan 23
2024
|
Faheem Hasnain |
SELL
Sale (or disposition) back to the issuer
|
Direct |
24,752
-58.24%
|
-
|
|
Jan 23
2024
|
Craig A Johnson |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,273
-58.12%
|
-
|
|
Jan 23
2024
|
Bruce L A Carter |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,273
-58.12%
|
-
|
|
Jan 23
2024
|
Aaron I. Davis |
SELL
Sale (or disposition) back to the issuer
|
Direct |
54,325
-72.93%
|
-
|
|
Jan 23
2024
|
Julie M Cherrington |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,252
-69.75%
|
-
|
|
Jan 23
2024
|
Shalini Sharp |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,222
-56.4%
|
-
|
|
Jan 16
2024
|
Benjamin Hickey EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,597
-0.68%
|
$94,223
$59.02 P/Share
|
|
Jan 16
2024
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,597
-0.51%
|
$94,223
$59.02 P/Share
|
|
Jan 08
2024
|
Benjamin Hickey EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,090
-1.73%
|
$121,220
$58.92 P/Share
|
|
Jan 04
2024
|
Jamie Christensen EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,531
-0.96%
|
$88,798
$58.81 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 327K shares |
|---|---|
| Open market or private purchase | 2.53M shares |
| Sale (or disposition) back to the issuer | 7.73M shares |
|---|---|
| Open market or private sale | 19.1K shares |